Secondary nonresponsiveness to botulinum toxin type A in patients with oromandibular dystonia

Authors

  • Charles H. Adler MD, PhD,

    Corresponding author
    1. Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
    • Parkinson's Disease and Movement Disorders Center, Department of Neurology, Mayo Clinic Scottsdale, 13400 E. Shea Boulevard, Scottsdale, AZ 85259

    Search for more papers by this author
  • Stewart A. Factor DO,

    1. Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
    Search for more papers by this author
  • Mitchell Brin MD,

    1. Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
    Search for more papers by this author
  • Kapil D. Sethi MD

    1. Parkinson's Disease and Movement Disorders Center, Mayo Clinic Scottsdale, Scottsdale, Arizona, USA
    Search for more papers by this author

Abstract

Intramuscular injection of botulinum toxin type A is the treatment of choice for most cases of oromandibular dystonia. We report on five patients with oromandibular dystonia that developed secondary nonresponsiveness to botulinum toxin type A following multiple injections over a 6-year period. © 2002 Movement Disorder Society.

Ancillary